Reports of suspected adverse reactions to COVID-19 vaccines in Switzerland – update

Bern, 26.11.2021 - Up to 23 November 2021, Swissmedic evaluated 10,386 reports on suspected adverse drug reactions to COVID-19 vaccinations that occured wit a temporal link to the vaccinations. At 6,756 (65 %), most of the reports were classified as not serious, while 3,630 (35 %) reports were classified as serious.

About half of the reports were submitted by medical professionals, while 5,232 or 50.4 % came directly from those affected, i.e. the patients.

The average age of those affected was 52.1 years, with 13.1% aged 75 or over. In the cases classified as serious, the average age was 54.8 years, and for reports temporally linked to a death it was 79.7 years.

In 159 serious cases, the people concerned died at differing intervals after receiving the vaccine. Despite a chronological correlation, there is no concrete evidence to suggest that the vaccination was the cause of death.

The majority of the reports concerned women and there were a few cases where no gender was specified. 7,129 (68.6%) reports involve Moderna's COVID-19 vaccine Spikevax® (for approx. 66% of the vaccine doses administered – this is the most widely used COVID-19 vaccine in Switzerland), while 3,007 (29 %) are associated with Pfizer/BioNTech’s Comirnaty® (approx. 34% administered vaccine doses).  The reports of adverse reactions received and analysed to date do not alter the positive benefit-risk profile of the COVID-19 vaccines used in Switzerland. This largely confirms their known side effects profile. Known side effects of COVID-19 vaccines are listed in the continually updated medicinal product information texts published on


Address for enquiries

Media Unit

+41 58 462 02 76


Swiss Agency for Therapeutic Products